Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands
Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the imaging CRO to support Celea’s Phase 3 SURPASS-IPF clinical trial.
Read original article on The Medical News →Related news
-
An inquiry into alleged COVID-19 vaccine injuries fails to weigh the ethics and risks of Canada’s response
Australia
-
A nine-year study reveals a pattern linking loneliness to heart risk
United Kingdom
-
Gut-friendly fiber formula gives hope to IBS sufferers
United Kingdom
-
Oxaloacetate supplement may help reduce chemo brain in breast cancer survivors
United Kingdom
-
How symptoms guide surgery decisions for people with thickened heart muscle
United Kingdom
-
Could a hormone from our bones reveal early signs of insulin resistance?
United Kingdom
-
Brazilian biobank may help personalize cancer prevention in the public health system
United Kingdom
-
10-Year-Old Dog Found after a Month Lost in Yellowstone
United Kingdom